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ABSTRACT 
Bone Mass Preservation and Fracture Risk Assessment 
with Bisphosphonate Therapy During Spaceflight 
Christopher Gardina 
Space exploration and microgravity have substantial negative effects on the 
human body. Symptoms of space explorers include cardiovascular deconditioning, bone 
loss, muscular atrophy, and impairment of neurovestibular and sensory function. The 
great loss of bone due long-duration spaceflight increases fracture risk, jeopardizing the 
success of the mission and postflight recovery. Bisphosphonates may be able to 
counteract this bone loss by altering the remodeling process. These drugs increase bone 
mass, thus reducing fracture risk, but also lead to increased levels of fatigue 
microdamage. Fracture risk can be lowered by increasing both bone mass (quantity) and 
bone quality. 
The purpose of this study was to create a computer model to simulate 
bisphosphonate treatment on astronauts while traveling in space in order to examine the 
ability ofbisphosphonates to maintain bone mass in a microgravity environment and 
reduce fracture risk of bone upon return to Earth. Various bisphosphonate treatment 
potencies and bone balance ratios given at different time points (either at or before 
spaceflight) were examined. Flight duration was also varied to examine short-term (10 
days) to long-term (1 year) effects of microgravity on bone mineral density (BMD), a 
measure commonly used to estimate bone strength, and damage accumulation. The model 
predicted bisphosphonate treatments with low to intermediate suppression of remodeling 
activation and that create higher bone balance ratios cause reductions in fracture risk. The 
simulation also predicted significant changes to BMD and damage upon return to Earth 
IV 
as the remodeling response readjusted to higher stress conditions. For treatments highly 
suppressing remodeling activation, these predicted postflight changes included decreased 
BMD and increased damage accumulation. Low levels of remodeling suppression led the 
model to predict substantial increases in BMD and small increases in damage postflight. 
Postflight changes were minimal for treatments with intermediate suppression. 
v 
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CHAPTER 1: INTRODUCTION
1.1 Spaceflight 
Microgravity has many adverse ctfects on the human body that hinder the ability 
of astronauts to explore outer space. The physiologic adaptations caused by unloading 
include cardiovascular deconditioning, bone loss, muscular atrophy, and impairment of 
neurovestibular and sensory function [1]. The focus here is on bone loss, which results 
from the reduced levels of stress caused by weightlessness. This loss poses a significant 
health risk for astronauts and is a major deciding factor of mission duration. In 6-month 
missions to the International Space Station (ISS), astronauts experienced up to 5 percent 
loss of bone mineral density (BMD) in the lumbar spine and 10 percent in the proximal 
femur [2]. On the MIR space station, the greatest bone loss observed in a crew member 
was on the order of half the mineral loss incurred in a Jj fetime of normal aging [3]. Upon 
return to Earth's gravitational envir nment, the average fracture risk for a space explorer 
paralleled the estimated level for 70- to 80-year old postmenopausal women [4]. While 
bone has the ability to recovery mineral, it is much slower than the rate at which it is lost. 
Complete recovery may take from I to 3 years, and in many cases bone will never fully 
recover the mineral lost during spaceflight [5]. 
NASA and other space exploration agencies have developed exercise programs to 
combat bone loss in space. In earlier space missions, exercise routines utilized bungee 
cords for resistive exercises, and stationary bicycles and treadmills for longer, aerobic 
exercises. More recent missions to the ISS combined these older techniques with a new 
piece of equipment, the Interim Resistive Exercise Device (iRED), focusing on resistive 
training. This apparatus, by sufficiently increasing loading intensity, may lead to shorter, 
more effective exercise routines [5]. Thus far, exercise routines have been able to slow 
bone loss, but remain unsuccessful at completely preventing it from occurring. NASA 
believes that coupling pharmacological treatments with their exercise programs will 
allow them to reach their goal [4]. Though the efficacy of many treatments such as 
testosterone, parathyroid hormone, calcium, vitamin D, and vitamin K, are being 
investigated, bisphosphonates seem a likely candidate [6]. Bisphosphonate therapy has 
the potential to increase bone mass in space just as it does for osteoporotic patients on 
Earth [2], though the pharrnacokinetic altering effects of spaceflight have yet to be 
determined. 
1.2 Properties of Bone 
In a healthy individual, bones provide structure and support, and with the help of 
muscles, tendons and ligaments, they allow for movement of the body. There are two 
distinct types of bone tissue: cortical or compact bone and trabecular (also referred to as 
cancellous or spongy) bone. The main difference between these two types is their 
porosity. Cortical bone is fairly dense and non-porous, while trabecular bone has a much 
higher porosity and is made up 0 f' struts' that form an interconnected matrix (F igures 1. 1 
and 1.2). Theoretically, the porosity of bone tissue can be anywhere from 0 to 100 
percent; however, it is almost always either very high (trabecular bone) or very low 
(cortical bone) and rarely in the intermediate range [7]. Cortical bone contains cylindrical 
units called osteons (Figure 1.1) and typically has a porosity of 5 to 10 percent. It can be 
found in the shafts and outermost layer of bone. Trabecular bone, normally 75 to 95 
percent porous, is contained deep inside the bone and is filled with marrow [7]. It is made 
up ofa matrix ofpackets of bone. 
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Figure 1.1. Illustration of long bone showing cortical and trabecular bone [8]. 
Figure 1.2. A healthy trabecular bone strut and one with inicrodamage [91. 
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Bone tissue experiences repetitive stress, leading to the formation of 
microdamage. Remodeling removes this damage, preventing fatigue failure from 
occurring under normal conditions [10]. Bone is made up of many packets of bone cells 
and minerals that are constantly undergoing this process. There are three major cells that 
partake in remodeling: osteoblasts, osteoclasts, and osteocytes. Osteoblasts and 
osteoclasts are bone-forming and bone-resorbing cells, respectively. Osteocytes are 
differentiated osteoblasts that are now fused into the bone matrix. Their role is to sense 
mechanical stimuli and send signals based on what they sensed to the surrounding bone 
cells [7]. The 3 to 4 month process of remodeling begins when osteoclasts receive signals 
to resorb damaged or fatigued bone. Osteoblasts then take over to remodel and 'fill in' 
the trenches created by the osteoclasts [7]. Together, osteoblasts and osteoclasts make up 
basic multicellular units (BMUs) of bone (Figure 1.3). 
Figure 1.3. A BMU containing osteoblasts and osteoclasts [Ill. 
BMUs are activated to remodel not only in response to increased microdamage 
[12,13,14,15], but also due to disuse situations where bone use is reduced [16,17]. 
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Exposing bone to fewer loading cycles or reduced load lowers the frequency or 
magnitude of strain experienced by the bone so that its current level of strength is no 
longer necessary. Bone is largely remodeled in order to minimize bone mass while 
maintaining the strength necessary to support the body [18]. The equilibrium point, where 
remodeling due to mechanical loading is such that bone resorption equals bone formation, 
varies from subject to subject. In general, as applied force and strain increase, the number 
of cycles required to maintain bone mass decreases [19]. 
1.3 Bisphosphonates 
Bisphosphonates provide new hope for long-duration space exploration. This 
class ofdrugs treats diseases with elevated bone remodeling by suppressing osteoclastic 
function [18]. Bisphosphonates suppress resorption upon physical contact with 
osteoclasts [20]. They have a high affmity for bone mineral [21] and bind to bone in areas 
where resorption has exposed hydoxyapatite [22]. There are a variety of bisphosphonates, 
each having different potency and cellular mechanisms inhibiting BMU activation [23]. 
The various potencies allow for a range in the degree of resorption suppression [24]. 
Bisphosphonates vary due to their chemical composition (Figure 1.4). First 
generation bisphosphonates, etidronate, clodronate, and tiludronate, did not have side 
chains containing nitrogen nor hydroxyl groups. These first bisphosphonates were less 
potent and did not specifically target bone as well as those from generation two [25]. 
Second generation bisphosphonates, including alendronate, pamidronate, and risedronate, 
each contain a hydroxyl group on the R1 side chain and have a chain containing nitrogen 
on R2. The hydroxyl group on the carbon atom causes the increased affinity for bone and 
the R2 chain determines the potency and mode of action ofthe drug [25]. The P-C-P 
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chemical substructure enhances the safety and efficacy of the compound by increasing 
the affmity for calcium and resisting the metabolic processes of the body [25]. Although 
newer bisphosphonates have a very high affmity for mineral, only about halfof any dose 
reaches bone [25]. Once they do reach bone and bind to exposed mineral, they can be 
uptaken by osteoclasts. While bound to osteoclasts, they exert their inhibiting effect by 
interfering with enzymatic activity. 
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Figure 104. Chemical structure of bisphosphonates. 
Bisphosphonates increase bone mass by reducing the temporary porosity created 
by remodeling known as the remodeling space, and by creating a positive bone balance 
where more bone is added than is removed [23,26]. Experimental data exists depicting 
the resulting bone mass increase in patients with osteoporosis. Spinal BMD increased 8.8 
percent and reduced vertebral fractures by 48 percent after 3 years of alendronate 
treatment [27]. Another study reported increased spinal BMD throughout 7 years of 
alendronate treatment on postmenopausal women [28]. 
Bisphosphonates also can have negative effects on bone. Lowered remodeling 
levels increase microdarnage accumulation and reduce toughness because less damage is 
removed [23]. Mineralization of the bones also increases, leading to brittler bones that 
6
are less resistant to crack propagation. One-year studies of alendronate and risedronate 
treatment on dogs showed microdamage accumulation and BMU activation frequency to 
be inversely proportional [29). The overall goal of these therapies is to minimize the 
amount of damage accumulated while increasing bone mass. In the long run, high 
potency bisphosphonate treatment may in fact be detrimental ifbone quality degrades 
enough to increase fracture risk due to high amounts of microdamage. Long-term effects 
ofbisphosphonates on bone remodeling still remain unclear. Since studies can take up to 
10 years to acquire real data, mathematically modeling the data and relationships 
obtained from shorter studies may be a more effective method of gathering insight into 
these phenomena. 
1.4 Previous Models 
Computational models are commonly used to test theories regarding the 
adaptation of bone to mechanical and physiological stimuli. Early models tested bone's 
mechanical adaptation. Carter et al. [30] and Huiskes et al. [31] were the first to use finite 
element modeling to develop mathematical relationships between mechanical loading and 
trabecular bone density [7). In their, model, Carter et al. [30] focused on a daily 
mechanical stimulus based on stress and an error function. The error function tracked the 
difference between the stress stimulus at a given time point and a predetermined 
equilibrium stress stimulus. The apparent density of each element in the model was 
adjusted according to the error function. New modulus values were calculated by 
multiplying the changes in density by a constant. These new values were used at the next 
time point to recalculate the daily stress stimulus for each element. 
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Huiskes' approach to model bone [31] has been shown to be the equivalent of 
Carter's but with different coefficients [7]. The model invoked bone adaptation by using 
strain energy density as the mechanical stimulus. New modulus values were calculated 
from strain energy density as in Carter's model [30] described above. The purpose of this 
particular model was to predict and analyze changes in bone due to total hip 
arthroplasties. Though both of these models were sufficient at simulating the mechanical 
environment that bone is subjected to, they did not include adaptations due to cellular 
responses. 
A model by Hazelwood et al. [18] incorporates responses to both mechanical and 
biological stimuli. The model takes into account the cellular responses ofBMUs. It 
predicts changes in porosity and elastic modulus based on simulated responses to 
mechanical stimuli such as disuse or overload and to the biological stimulus of damage 
accumulation. The schematic below (Figure 1.5) shows the basis for the simulation. Note 
that damage and disuse affect BMU activation frequency, which in turn affects porosity 
and modulus. The schematic shows remodeling to be a dynamic loop. 
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Figure 1.5. Schematic ofa bone remodeling algorithm by Hazelwood et a1.1181. 
In early computational models simulating bisphosphonate effects, the basic 
strategy was to match clinical results of the treatment. The models simulated varying 
parameters such as BMU activation frequency, resorption and formation periods, bone 
balance, and mineralization [32,33,34,23], but failed to include other stimuli important to 
long-term changes to BMD. These models did not take into account bone remodeling due 
to mechanical loading nor microdamage accumulation. Heaney et al. [32] developed a 
model that was fairly accurate when predicting bisphosphonate effects on BMD out to 6 
months. The model simulated treatment using the bone balance method of decreasing 
bone turnover, decreasing remodeling space, increasing focal bone balance, and keeping 
bone mineralization constant. Hernandez et al. [33] developed a model to compare this 
method with the mineralization method in which remodeling space is decreased, focal 
bone balance remains the same, and bone mineralization is varied. This model included a 
longer secondary mineralization period to account for increases to BMD in the long term. 
9
The schematic shown in Figure 1.6 shows the lack of mechanical stimuli in the model 
developed by Hernandez et al. [33]. Lacy et al. [34] developed a model of 
bisphosphonate treatment in which various parameters were closely analyzed. Activation 
frequency was found to have the greatest influence on predicting changes in bone volume 
[34]. 
BMU lifespan 
(Number of " Timc-
TerminatIng BMUs) 
Number of 
Progressing BMUs 
Originalion Frequency / 
(Number of New BMUs) 
Sum of all BMUs Sum of all BMUs 
with active actively forming 
formation osteoid 
"Local Formation 
Rate 
~ 1\Volume of 
Volume of Change in osteoidbone resorbed 
bone formed volume 
Figure 1.6. Schematic of a bone remodeling algorithm by Hernandez et al. 1331. 
A model developed by Nyman et al. [23] utilized both mechanisms of remodeling 
described previously, in response to mechanical loading and damage accumulation, to 
simulate the long-term effects ofbisphosphonate usage. The model was designed for 
examining postmenopausal osteoporosis, so it also included a bone remodeling response 
to estrogen deficiency. The results of the model showed that the reduction of resorption 
space caused by bisphosphonate treatment played a key role in increasing bone volume 
over the long run. Also, Nyman et al. [23] concluded that the disuse response contributed 
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to the eventual plateau of bone gain that other models failed to achieve [32,33]. Overall, 
the model showed incomplete suppression ofBMU activation frequency and positive 
bone balances to permanently increase bone vo lume with minor gains in microdarnage 
accumulation [23]. Various aspects of this model are implemented in this study and will 
be covered in more detail in the next section and in the methods chapter. 
1.5 Simulating Bisphosphonate Treatment during Spaceflight 
The goal of this study is to create a computer model to simulate bisphosphonate 
treatment on astronauts while traveling in space in order to examine bisphosphonates' 
ability to maintain bone mass in a microgravity environment and reduce fracture risk of 
bone upon return to Earth. We will examine various bisphosphonate treatment potencies 
and bone balance ratios given at different time points (either at or before spaceflight). 
Flight duration will also be varied to examine short-term (10 days) to long-term (l year) 
effects ofmicrogravity on BMD and damage accumulation. To examine these effects, 
mathematical relationships modeling bisphosphonate therapies [23] were applied to a 
computational model developed by Hazelwood et al [18] that was modified to investigate 
the influence ofmicrogravity on the bone remodeling process. 
This simulation will not only increase the understanding of the effects of 
spaceflight and bisphosphonate usage, but it may also lead to advances ofother proposed 
treatments such as parathyroid hormone, testosterone, and vitamin K2 [6]. Understanding 
each therapy will eventually lead to better treatments on Earth and in space, decrease the 
health risks of space travel, and drastically expand the bounds of human space 
exploration. 
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CHAPTER 2: METHODS
2.1 Mechanical Loading 
This model simulates cyclic uniaxial loading ofa volume of vertebral trabecular 
bone (Figure 1.1). Applying data from previous studies [35,36,37], and assuming a linear 
relationship between apparent density and porosity allows apparent stiffuess (elastic 
modulus, E) to be determined, 
E=Eox(l-p),b (1 ) 
in units of MPa, where p is porosity, and 14927 and 1.33 are values of Eo and b, 
respectively, for trabecular bone [18]. Bone mineral density (BMD) was calculated by a 
porosity relationship, 
BMD = p x (l - p), (2) 
where p is apparent density of bone (2.0 g/cm3 when p = 0) [18]. Apparent density is the 
measure of mass per unit volume, including the voids spaces within the material. 
Peak strain was calculated using Hooke's Law, 
E = a/E. (3) 
The mechanical stimulus modeled to stimulate the bone volume's response to remodeling 
was defined as 
(4) 
where RL is the loading frequency in cycles per day and q adjusts the peak strain and 
loading frequency to correctly model the loading potential [18]. 
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2.2 Porosity Transformation 
The rate of change of porosity (P) is the difference between the amount of bone 
formation and amount of bone resorption per given time period [38,39]. It is defined as 
(5) 
where QR and QF are the mean bone resorbing and refilling (forming) rates, and NRand 
NF are the densities of resorbing and refilling BMUs per area, respectively. The rate of 
resorption, 
(6) 
and rate of refilling, 
(7) 
are assumed to be linear in time [40]. The area of bone resorbed (A R) and area of bone 
formed (A F) were based on a cement line radius of 0.095 mm [40]. When bone is in a 
disuse state (<1> < <1>0), refilling is reduced on bone surfaces [41]; thus, area of bone 
formed during disuse was reduced to A [0.5 + 0.5(<1>/<1>0)] [18]. The resorption (TR) and 
refilling (TF) periods were 25 and 64 days, respectively [23]. These periods were used to. 
calculate total number ofresorbing BMUs and refilling BMUs per given area. Integrating 
BMU activation frequency,};, (BMUs/area/time), over a known time period will result in 
the number per section area of resorbing BMUs, 
I 
N R = Jfa (t')dt', (8) 
I-T. 
and the number per section area of refilling BMUs, 
I-(T.+T, ) 
N F = Jfa (t')dt' . (9) 
I-(T. +Tf +TF ) 
Present time is t and T, is a latency period between resorption and refilling [23]. 
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2.3 BMU Activation 
BMU activation frequency, as previously mentioned, is the number ofactive 
BMUs in the section area per day. It is assumed to be a function of the two remodeling 
mechanisms mode led by Hazelwood et al. [18], damage and disuse. Activation frequency, 
(10)fa = (fa(diSUSe) + fa(damage»)S A , 
is also a function of internal surface area as BMUs must begin on a bone surface [18]. SA 
is internal surface area per unit volume normalized to values between 0 and I by SArnax. It 
was determined by using a porosity-surface area relationship developed by Martin [42] 
2 3 4 5)SA = (32.lp - 93.9p + 134p - 101p +28.8p / SArnax. (11) 
This accounts for decreased remodeling in bone volumes with smaller surface areas. 
Changes in activation frequency due to damage and disuse were modeled 
assuming sigmoidal relationships [18] between damage and h(damage), 
f (fao )(fa(max) ) 
a(damage) - J: + (J: - J: ) [k,(fo(n~,»)(D-Do)1Dol' (12)
aO a(max) aO e
and mechanical stimulus andfa(disuse), 
fa(max) fc <I> <I>J:a(disuse) = k (CI>-k) or < 0 • (13)1+ e b , 
The k values were determined by matching the curves to clinical data [18]. Coefficients kr, 
kb, and kc define the shape, slope, and inflection point of the curves, respectively. The 
maximum activation frequency (fa(max)) of 0.50 BMUs/mm2/day was higher than the 
highest measured activation frequency (0.14 BMUs/mm2/day) for human cortical bone 
because it is assumed the measurements did not reach the upper limits [43,18]. 
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2.4 Microdamage Accumulation 
Microdamage (D) is defmed as total crack length per section area of bone. 
Damage accumulation due to fatigue is modeled according to Martin's work [44] as 
(14) 
where DFand DR are the damage formation and removal rates, respectively. Based on 
Martin's findings, we assumed the rate of damage formation to be proportional to the 
loading potential [18], 
DF=kDx<l>. (15) 
This model assumes a random distribution ofBMUs and damage in the section area of 
bone; however, a damage removal specificity factor is included when modeling the rate 
of removal due to evidence showing that damage initiates the activation ofBMUs [9,10, 
14,15,18], 
tJR = DfaARFs . (16) 
The specificity factor, Fs , was assumed to be 5 based on experimental data [44]. Initial 
equilibrium is defined here as the time at which the rate of damage formation is equal to 
the rate ofdamage removal [18]. Setting both equations equal allows us to determine the 
damage rate coefficient, 
(17) 
where initial, equilibrium values are designated by the subscript O. These values were 
obtained from Hazelwood et al. [18]. 
2.5 Preflight Conditions 
Before applying microgravitational conditions, preflight parameters were 
calculated (Table 2.1) using constants derived from experimental data (Table 2.2). These 
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parameter values were obtained by executing the model developed by Hazelwood et al. 
[18] until the values reached equilibrium. The applied stress on earth modeled to reach 
these values was determined by matching the predicted bone porosity of the model to 
0.78, a porosity typical of vertebral trabecular bone in adult males in Earth's gravitational 
environment [45,46,23]. The calculated applied stress, 1 MPa, was based on a 100 mm2 
cross-section from the modeled 1 cm3 trabecular bone volume (Figure 2.1) [23]. The 
resulting preflight BMD was 0.44 g/cm3. 
Table 2.1. Model parameters with values obtained from simulating remodeling in trabecular 
bone beIiore ent·erm~ s ace and at the end of a 180 d - . I fay space slmu a IOn. 
Preflight End of flight values 
Parameter (units) Description trabecular bone (180-day) 
E (MPa) Elastic modulus 1992.3 188\.9 
P Porosity 0.780 0.789 
BMD (g/cm3 ) Bone mineral density 0.4400 0.4215 
e (10'6) Microstrain 50\.9 473.4 
¢ (10. 1°) Loading potential 1.904 1.507 
D (mrn/mm2 ) Total crack length per 
section area 0.0375 0.0327 
. 2DF (mrn/mm /day) Damage formation rate 0.0000353 0.0000280 
DR (mrn/mm2/day) Damage removal rate 0.0000353 0.0000417 
BMUs appearing in thefa (BMUs/mm2/cfay) 0.0133 0.0180
section area per day 
NF (#/mm2) Number of refilling sites 0.8495 1.2825 
NR (#/10102) Number of resorbing sites 0.3318 0.4483 
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Table 22.. Remo·dCr109 slInu a Ion CODStaD ts 
Constant (units) Description 
AF (nun 2) Area of formation 
AR (mm2) Area of resorption 
AR(u) (mm2) Area or resorption (reduced by 1/6) 
AR(lJ) (mm2) Area of resorption (reduced by 3/13) 
TR (days) Resorption period 
T[ (days) Reversal period 
TF (days) Refilling period 
kD (mm/mm2 ) Damage rate coefficient 
Rdcpd) Loading rate 
q Damage rate exponent 
F., Damage removal specificity factor 
Do (mm/nun2) Initial damage 
fao (BMUslnun2/day) Initial BMU activation frequency 
([>0 (cpd) Initial mechanical stimulus 
(Je (MPa) Stress applied on earth 
(Js (MPa) Stress applied in space 
fa(max) Maximum BMU activation frequency (BM Uslmm2/day) 
SA (mo.,) Max. specific surface area, nonnalizing constant 
kb (cpd-!) Activation frequency dose-response coefficient 
kc (cpd) Activation frequency dose-response coefficient 
kr Activation frequency dose-response coefficient 
Nominal 
value Source 
1.418 x 10-2 [23] 
1.418 x 10_2 [23] 
1.181 x 10_2 [23] 
1.090 x 10_2 [23] 
25 [23] 
5 [23] 
64 [23] 
-1.85 x 105 [18] 
3000 [ 18] 
4 [47] 
5 [44] 
0.0366294 [ 14,48] 
0.0067 [49] 
1.875 x 10- 10 [18] 
I 
0.8909 
0.5 [18] 
4.195 [ 18] 
6.5x 10 10 [18] 
9.4 x \0-11 [18] 
-1.6 [18] 
Figure 2.1. Trabecular volume and cross-section 123). 
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2.6 Simulation of Spaceflight 
Microgravity was simulated by lowering the stress applied to the bone volume. 
Astronauts experienced an average vertebral trabecular BMD loss of 0.7% per month, for 
a total of 4.2% BMD loss during the 180-day average ISS missions [3,5,6]. For this 
simulation, stress applied to the representative volume during spaceflight was then 
determined as 0.8909 MPa based on this 180-day spaceflight ending density of0.4215 
g/cm3. 
Using the density loss values at 180 days as a baseline, various durations of 
spaceflight were simulated based on typical mission length for astronauts, including 10 
days, 90 days, and 180 days [5,4]. Though 365 days in space is not typical, it was also 
simulated to examine the potential of bisphosphonates to maintain BMD without 
increasing damage. 
2.7 Simulation of Bisphosphonates 
Bisphosphonate treatment was simulated using two factors: one lowering 
activation frequency and the other reducing the resorption area. A potency variable (P), 
where 0 < P::: 1, is applied to exert the former effect by multiplying.fa by the quantity (1 
- P). P is based on pharmacokinetic properties ofbisphosphonates, including potency 
factors, binding, uptake, and mode of action [23], 
P = Pmax(l - e-Ts x NR). (18) 
Pmax and Tsare suppression coefficients reflecting various properties ofbisphosphonates 
in order to model a range of drug potencies. Values for these coefficients (Table 2.3) 
were selected based on the experimental results from 1 year studies ofdaily alendronate 
and daily pamidronate treatment, and modeled the variations in the reduction of 
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activation frequency as seen in these studies [23]. Figure 2.2 displays the effects ofthe 
coefficients on the relationship between P and NR. 
B O d dOth ° I tiT able 23.. ISPhosphonate e fliects analyze unng e slmu a on. 
Initial 
Level of bone 
Treatment Label suppression Pm ax Ts balance 
no treatment POa1 - 0 0 1 
A P07t5a12 Low 0.7 5 1.2 
B P07t20a12 0.7 20 1.2Intermediate 
C P1t5a12 1.0 5 1.2 
0 P1t20a12 High 1.0 20 1.2 
E P07t5a13 Low 0.7 5 1.3 
F P07t20a13 0.7 20 1.3Intermediate 
G P1t5a13 1.0 5 1.3
H P1t20a13 High 1.0 20 1.3
0.81--1-----/--------------------1 
0.6 
P (Pmax, Tau) 
P(1,5) 
P(1,20) 
P(0.7,5) 
-P(0.7,20) 
0.4 +-If-l-----j<--------­
0.2 +....1-1---------­
O-l----~--~---~--~---~--~--___i
o 0.2 0.4 0.6 0.8 1.2 1.4 
Figure 2.2. Bisphosphonate potency as a function of number of resorbing BMUs. 
The size ofthe resorption cavity is reduced during bisphosphonate treatment due 
to their effects on osteoclasts [23], resulting in alterations to the ratio of bone area formed 
to bone area removed. Two different initial bone balance ratios (AFiAR) for the simulation 
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ofbisphosphonate treatment were used (Table 2) based on reductions of 1/6 and 3/13 to 
resorption area found in postmenopausal women treated with bisphosphonates for I year 
[23]. A bone balance of 1.0 is assumed for the simulation when bisphosphonate treatment 
is not in effect. 
Bisphosphonates were simulated during the entire spaceflight. Prefljght treatment 
was also examined, where bisphosphonates were applied to the simulation at 0, 7, 14,30, 
90, and 180 days preflight. 
2.8 Simulation of Return to Earth 
The return to earth was modeled by resuming preflight bone loading conditions, 
with an applied stress of 1 MPa. Once back on Earth, bisphosphonate therapy was 
discontinued. The simulation was extended 365 days postflight to examine increases or 
decreases in fracture risk based on bone mineral density and damage accumulation. 
Though it takes 1 to 3 years to fully recover without treatment, a one year postflight 
examination allowed us to determine if a treatment is successful at maintaining bone 
mass without accumulating more damage. A successful treatment will cause the 
remodeling properties to reach new equilibrium values within one complete remodeling 
cycle (3 to 4 months) after arriving back on Earth. 
2.9 Model Implementation 
The computational model was coded in MATLAB (Appendix A). The time 
increment for which all the model variables were updated and tracked was I day. The 
computational simulation was executed in Windows Vista (32-bit) using an Intel Core 2 
Duo processor. 
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2.10 Postflight Parameter Analysis 
Together, bone mass (quantity) and bone quality determine the ability of bone to 
resist fracture [50,51]. For this simulation, we examined changes in bone mass and bone 
quality in terms ofBMD and microdamage accumulation, respectively. Experimental 
results from ex vivo studies have shown BMD to predict 66 to 74 percent of the variation 
in bone strength [52]. An increase in bone mass and bone quality will lead to stronger, 
more fracture resistant bone; thus, in the analysis we assumed higher BMD and lower 
damage accumulation to lead to higher fracture resistance. 
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CHAPTER 3: RESULTS
3.1 Untreated Spaceflight 
The model's results were consistent with experimental data obtained from 
spaceflight [4] in that the predicted BMD loss was non-linear (Figure 3.1). Predicted 
damage accumulation decreased as flight duration increased (Figure 3.1) due to the 
disuse response in which damage was specifically targeted during resorption and because 
less damage formed each day due to the microgravity environment (Figure D25). The 
predicted rate ofBMD loss was greatest early on in the flight, showing smaller 
decrements as time spent in space increased. The model predicted little BMD loss and 
change from preflight damage for the typical flight duration of 10 days (Figure 3.1); 
however, postflight predictions showed that BMD continued to decrease upon return to 
Earth until it reached a value nearly 3 times lower than it was at the end of the mission 
before increasing to near normal levels about 100 days after entering Earth's gravity 
(Figure Bl). 
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Figure 3.1. Predicted percent decreases in HMO and damage (0) of untreated bone at end of 
spaceflight. 
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Figure 3.2. Predicted effects of ISO-day spaceflight on HMO of untreated bone from beginning of 
flight through 19.5 years postflight. 
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Figure 3.3. Predicted effects of ISO-day spaceflight on damage accumulation (0) of untreated bone 
from beginning of flight through 19.5 years postflight. 
For the 180-day space mission, the predicted postflight results for untreated bone 
showed sharp increases to both BMD and damage upon return to Earth (Figures 3.2 and 
3.3). BMD reached equilibrium approximately 7 years postflight, and was about 2.7% 
less than its preflight value. Damage continued to accumulate postflight until equilibrium 
was reached about 15 years after the return to Earth. Though damage was initially lower 
upon return to earth, it continued to increase postflight until reaching a value 
approximately 9.5% higher than its preflight value. Figures 3.2 and 3.3 clearly indicate a 
need for treatment as bone was negatively affected by decreased mass and quality. 
Also noteworthy is the predicted oscillatory behavior ofBMD values seen in 
disuse (Figures 3.2 and 3.15) for untreated bone. The inflection points are located 
approximately at the same intervals as the transitions from resorption to refilling and 
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refilling back to resorption in the BMU remodeling period. This oscillatory trend was 
also noted in the model by Hazelwood et al. [18] and still needs further investigation. 
3.2 Bisphosphonate Treatment Onset at Beginning of Spaceflight 
The simulation predicted gains in BMO for shorter flights (10 and 90 days) in 
which treatments exhibited intermediate to high suppression (Figures 3.4 and 3.5). For all 
flight durations, high suppression ofBMU activation (Table 2.3) led the model to predict 
increases in both BMO and damage accumulation. Overall, the model predicted 
treatments creating bone balances of 1.3 to have more positive effects on BMO (i.e. less 
loss or greater increase). Although those with bone balances of 1.3 positively affected 
BMO, the model predicted that they also caused more damage to accumulate when the 
level of remodeling suppression was high. In general, the model predicted treatments 
with intermediate levels of suppression to have smaller changes in BMO at the end of 
spaceflight than the decreases predicted with low levels 0 f suppression and than the 
increases predicted with high levels of suppression. Also, the simulation predicted that 
treatments with intermediate suppression caused end-of-flight BMO and damage 
accumulation values of to remain closer to the pretreatment, preflight values than 
treatments with low or high remodeling suppression. 
As flight duration increased, predicted percent changes in damage and BMO 
increased. Simulations oflong flight durations (180 and 365 days) resulted in significant 
changes, predicting treatments with low and intermediate suppression to have significant 
decreases in damage (up to 14.5%) similar to untreated bone. The greatest predicted 
increases in both damage and BMO occurred for treatments of high suppression and bone 
balances of 1.3. Simulation of treatments C, E, F, and G (Plt5a12, P07t5a13, P07t20a13, 
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and Plt5a13), with low and intermediate levels of remodeling suppression, showed 
increases in BMD and decreases in damage accumulation on longer duration spaceflights 
(Figures 3.6 and 3.7). 
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Figure 3.4. Predicted percent changes in HMD and damage (0) at end of IO-day spaceflight. 
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Figure 3.5. Predicted percent changes in HMO and damage (D) at end of 90-day spaceflight. 
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Figure 3.6. Predicted percent changes in HMO and damage (D) at end of 180-day spaceflight. 
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3.3 Preflight Bisphosphonate Treatment 
In accordance with data obtained from clinical studies [21], the predicted results 
ofbisphosphonate treatment on Earth exhibited increases in HMO and damage 
accumulation. Predicted pre-spaceflight additions to HMO and damage continued to rise 
as the duration of the preflight therapy simulation increased from 7 to 180 days (Figures 
3.8-3.12). The model showed damage to increase at a faster rate than HMO. The ratio of 
percent increase in damage to percent increase in BMO, used in this study as a measure 
indicating efficiency ofreducing fracture risk in which a lower value is more optimal, 
was highest for treatments with high levels of remodeling suppression, and especially for 
those also with lower bone balances (Table 3.1). The lowest ratio of percent preflight 
increase of damage to HMD was predicted for Treatment E (P07t5a13), which modeled 
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12.0 
low remodeling suppression and a bone balance ratio of 1.3. Bisphosphonate treatments 
with lower suppression of BMU activation and higher bone balance ratios proved to be 
optimal by adding more healthy bone per increase in BMD. 
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Figure 3.8. Predicted preflight increase in HMD and damage (0) due to 7-day preflight treatment. 
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Figure 3.9. Predicted preflight increase in BMD and damage (0) due to 14-day preflight treatment. 
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Figure 3.10. Predicted preflight increase in BMD and damage (0) due to 30-day preflight treatment. 
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Figure 3.11. Predicted preflight increase in BMD and damage (D) due to 90-day preflight treatment 
12.0,---------­
11.0 
10.0 
9.0 
~
8.0
:I " Ii 
> 
1: 7.0 ~
10
!! 6.0l! 
Q. 
E 5.0 ~
& 
4.0 ­iii 
.s:. 
U 
3.0 
2.0 
1.0 
0.0 
P07tSa12 P07t20a12 PlISa12 P1t20a12 P07tSa13 P07t20a13 PlI5a13 P1I20a13
Bisphosphonate Treatment
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Table 3.1. Ratio of percent prefli2ht increase of dama2e (D) to BMD. 
%~D:%~BMD for Number of Days of Preflight Treatment 
7 14 30 90 180 
P07t5a12 2.83 2.08 1.37 1.55 2.25 
P07t20a12 2.91 2.30 1.48 1.66 2.80 
P1t5a12 3.17 2.29 1.39 1.66 2.62 
P1t20a12 3.39 2.49 1.44 1.76 3.14 
P07t5a13 2.44 1.88 1.32 1.47 1.98 
P07t20a13 2.52 2.04 1.42 1.60 2.55 
P1t5a13 2.72 2.04 1.34 1.58 2.35 
P1t20a13 2.92 2.26 1.40 1.71 2.96 
3.4 Varying Onset of Bisphosphonate Treatment for Spaceflight 
For longer durations in space, the model predicted pretreatment periods to become 
less effective at influencing the end-of-flight values for BMD and damage (Figure 3.7, 
3.13, and 3.14). As duration in space increased, the model predicted end-of-flight values 
to be influenced more by the effects of spaceflight than the effects of preflight treatment. 
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Figure 3.13. Predicted percent changes in BM D and damage (D) at end of 365-day spaceflight due to 
30-day preflight treatment. 
32
20.0 
-­
15.0 
10.0 
e 
II
::I
Ii 50> 
i 
li 
e 0.0 f 
Cl. 
E 
£
.. -5.0 
'" ..
"1:. 
l.) 
-10.0 
-15.0 
-20.0 
Bisphosphonate Treatment Given 180·Days Preflight (att: .180) 
Figure 3.14. Predicted percent changes in HMD and damage (D) at end of 365-day spaceflight due to 
180-day preflight treatment. 
Alternately, pretreatment phases highly influenced the model's predictions ofBMD and 
damage for shorter durations of spaceflight. For nearly all bisphosphonate potencies 
simulated, the addition of preflight treatment caused increased BMD and damage 
accumulation at the end of IO-day spaceflight. For 90-day spaceflight, a pretreatment 
period of30 days predicted increases in BMD without significantly increasing damage, 
and the same occurred with a 90-day pretreatment for I80-day spaceflight. Also, adding 
preflight treatment for therapies with high suppression predicted further increases to the 
already large gains in BMD and damage that occurred without pretreatment. 
3.5 One-Year Postflight, Posttreatment Recovery 
The model predicted treatments with low levels of remodeling suppression given 
initially at the beginning of spaceflight to result in the highest BMD and lowest 
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microcrack density accumulation I-year after returning to Earth (which is also I-year 
posttreatment). Treatments with high suppression, though they resulted in higher BMD at 
the end of flight, were predicted to generate the lowest BMD of all the applied treatments. 
Predicted I-year postfught values for BMD and damage for treatments with intermediate 
levels of remodeling suppression were between the two extremes (Figures 3.15 and 3.16). 
Note that bisphosphonate treatment begins where the x- and y-axes meet for the line 
graphs that display timelines of prefught through I-year postfught predicted values. 
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Figure 3.15. Predicted bispbospbonate effects on BMD and posttreatment return to Eartb from 180­
day spaceflight. 
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Figure 3.16. Predicted bisphospbonate effects on HMD and posttreatment return to Earth from 180­
day spaceflight. 
Upon return to Earth, predicted damage accumulation increased for treatments 
given at the beginning of spaceflight that created bone balances of 1.2 (Figure 3.17). This 
was the opposite case for bone balances of 1.3, where the model predicted further 
decreases in damage post-flight and post-treatment (Figure 3.18), except in the case of 
365-day spaceflight where predicted damage loss was substantial during flight (Figure 
3.19). Prediction results for treatments with high levels of remodeling suppression did not 
follow these trends, as they always led to decreases in damage during postflight recovery. 
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Figure 3.18. Predicted bisphosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from 180-day spaceflight. 
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Figure 3.19. Predicted bisphosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from 365-day spaceflight. 
The predicted gains in BMD due to preflight treatment appear to have increased 
the ability to recover from spaceflight as predicted BMD and damage nearly reach 
pretreatment values (Figures 3.20 and 3.21 for bisphosphonates given 90 days preflight. 
See appendices B, C, D, and E for treatment results for 10-, 90-, 180-, and 365-day 
spaceflights, respectively.). Most of the predicted values for BMD and damage either 
were near or reached equilibrium after I-year of postflight recovery. The model predicted 
I-year postflight recovery values for BMD and damage to be both above and below 
pretreatment values, depending on the treatment. 
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Figure 3.20. Predicted bisphosphonate effects beginning 90 days preflight on BMD and 
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CHAPTER 4: DISCUSSION
The computer model developed here combines previous bone remodeling and 
bisphosphonate algorithms plus spaceflight data obtained from experimental studies in 
literature in order to better understand the adverse effects of microgravity on bone and 
predict potential treatments for space explorers. The model predicted reduced risk of 
fracture by increasing bone quantity and either increasing or only slightly reducing bone 
quality for treatments (1) with low to intermediate suppression of remodeling activation 
and (2) that create higher bone balance ratios. The simulation also predicted significant 
changes to BMD and damage upon return to Earth as the remodeling response readjusted 
to higher stress conditions. For treatments highly suppressing remodeling activation, 
these predicted postflight changes included decreased BMD and increased damage 
accumulation. Low levels of remodeling suppression led the model to predict substantial 
increases in BMD and small increases in damage postflight. Postflight changes were 
mjnimal for treatments with intermediate suppression. 
The model was developed to match the 4.2 percent loss in BMD over 180 days in 
space as seen on the International Space Station [3,5,6]. The model's greatest predicted 
BMD loss in untreated, trabecular vertebral bone was 5.0 I percent for a 365-day 
spaceflight. This is less than half the highest loss (-10.8 percent) seen in Russian 
cosmonauts on Salyut missions lasting 5 to 7 months [5]. Though the model does not 
match the results from these older missions, it is likely due to advancements in 
technology, physical preparedness of subjects, and onboard exercjse routines that were 
developed for missions to the International Space Station. 
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Full recovery for space explorers returning from the ISS took from I to 3 years to 
complete [5]. The model developed here predicted that full recovery to preflight BMD 
values may never be attained without treatment. With bisphosphonate treatment, the 
model predicted complete recovery to occur; some treatments even resulted in higher 
BMD values than existed preflight. The model suggests that bisphosphonate treatment, 
combined with exercise, may be the solution that NASA and other space exploration 
programs desire to combat bone deterioration in space. 
The predicted remodeling response of untreated bone to environmental changes 
was non-linear, as most BMD was lost or gained early on in the transitions from Earth to 
space and space to Earth. For 10 days in space, the model predicted more mineral to be 
lost while readjusting to Earth's gravity than lost during spaceflight. This has yet to be 
examined experimentally, but certainly the model provided insight into a possible trend 
that may have gone unnoticed. Knowing when fracture risk is maximized may provide 
for better postflight recovery programs so that fracture can be avoided. 
The model predicted bisphosphonate treatment to be beneficial for all durations of 
spaceflight, not just for longer duration missions. In many instances, preflight treatments 
were shown to reduce the fracture risk upon return to Earth. Longer simulated flight 
durations required longer preflight treatments to provide similar effects to those with 
shorter flights and shorter pretreatments. The problem with this is that as treatment on 
Earth is lengthened, damage accumulation increases to such an extent that it could 
actually cause an increase in fracture risk before entering space. Based on the model's 
predictions ofdamage increase, pretreatment periods longer than 30 days may put the 
subjects at risk. During pretreatment, the subjects are still on Earth where higher stresses 
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cause greater increases in damage as compared to space. They may also be exposed to 
even higher stresses due to exercises in preparation for the mission. These exercises, 
combined with brittler bones, could lead to a fracture before flight and put a hold on the 
mission. 
Most interestingly, the model predicted treatments with high suppression of 
remodeling activation to have the highest gain in BMD at the end of flight, and the lowest 
BMD values I-year postflight. These treatments almost completely inhibited remodeling, 
causing large amounts of damage to accumulate. Though BMD was much higher, the 
quality of bone was poor. Upon return to earth and discontinuation of treatment, bone 
remodeling was no longer inhibited and responded to the high amount ofdamage. 
Damage and bone were removed at a much greater rate than bone formation occurred, 
causing quality of bone to increase, but quantity to decrease. 
Alternately, the model predicted treatments with low suppression of activation 
frequency to have the lowest BMD at the end of spaceflight, but they had the highest 
BMD and lowest amount ofdamage I-year postflight. These treatments allowed a fair 
amount of remodeling to continue in space, but limited it enough so that bone loss was 
kept to a minimal amount. A majority of the predicted bone loss came from lost damage, 
so upon return to earth damage accumulation did not activate a remodeling response. 
These treatments had the largest postflight gains in BMD because the response was 
mostly due to loading in which bone was added to meet the strength required to support 
the subject. 
Treatments with intermediate suppression and bone balance ratios of 1.3 were 
optimal for both end-of-flight and I-year postflight. The model predicted these treatments 
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to lower risk of fracture both upon return to Earth and after 1 year of recovery. Lower 
levels of suppression allowed just enough resorption to remove a good amount of fatigue 
microdamage and increase bone quality, while higher bone balances appropriated more 
formation than resorption, increasing bone mass. 
Since the simulation of bisphosphonate treatment in this model was short in 
comparison with other models, it is difficult to determine if limits ofBMD growth were 
reached. Predicted BMD gains were non-linear and fluctuated throughout the simulation; 
in contrast, previous models that did not account for damage and disuse stimuli showed 
only permanent, linear gain in mass [32,33,34]. 
Similar to Lacy's model of trabecular bone turnover [34], activation frequency 
was found to have the greatest effect on bone mass. Unloading in microgravity caused a 
disuse response in untreated bone, increasing BMU activation and leading to the 
resorption of large amounts of bone. The model by Hernandez et al. [33] also showed 
similar results in that the initial gain in bone mass was dependent upon the level of 
remodeling suppression and bone balance ratio. Heaney's model [32] exhibited an initial 
gain dependent upon the pretreatment remodeling parameters; however this model did 
not examine variations in these parameters before treatment. 
It is difficult to compare the accumulation ofdamage of this model to others since 
it also simulates rnicrogravity. The model by Nyman et al. [23] predicted small gains in 
microdamage initially that were proportional to activation frequency suppression. In 
contrast, the model developed here predicted losses in microdamage for treatments with 
low and intermediate levels of suppression and gains in damage accumulation when 
activation frequency was highly suppressed. 
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The limitations ofthis model occur where assumptions have been made due to the 
lack of available information. First, the damage rate coefficient, kD , was kept constant 
throughout the simulation, though it is likely to change in space or for various bone 
balances. Other coefficients, too, such as the damage rate exponent or the activation 
frequency coefficients, are likely to be altered in space and would benefit from further 
study of bone remodeling in microgravity. Second, the predicted postflight results are 
limited by the fact that they are based on the same stress applied preflight even though 
postflight recovery programs enable space explorers to ease back into full loading. This 
high postflight stress would cause overpredictions of both BMD and damage. Also, a 
bone balance ratio of 1.0 was instantly applied upon return to Earth, when it is more 
likely that the ratio would slowly ease back down. Third, the simulation applies a 
constant stress derived from bone loss to a section of bone rather than deriving the actual 
strain and applying it to a finite element model. Using a finite element model would 
create a more accurate remodeling response with more precise loading conditions and 
allow detailed analysis of the effects of specific exercises on maintaining bone mass. 
Lastly, the model does not take into account effects of spaceflight on blood flow, drug 
metabolism, tissue binding, drug elimination, fluid shear stress, or changes in hormone 
levels [2,4]. Many of these affect the efficacy of the drug itself Changes to fluid shear 
stress in a microgravity environment could affect the mechanosensory ability of 
osteoclasts to sense signals indicating bone loading and would lead to further loss of bone 
even under heavy exercise [4]. Also, although the model tracks changes to the 
populations of osteoblasts and osteoclasts, it only accounts for changes due to the 
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remodeling response and not due to the physiological adaptations that may occur in 
microgravity [2]. 
Changes in hormone levels or physio logical alterations to the populations of 
osteoblasts or osteoclasts could significantly alter the remodeling response in space and 
the response to bisphosphonate treatment [4]. With reduced levels ofPTH, IGF-I, and 
growth hormone [4], it would be likely for remodeling formation and resorption rates to 
be altered in microgravity. With so little bone formation occurring, it could also be 
possible that active osteoclasts may significantly outnumber osteoblasts and lead to a 
slower recovery response upon return to earth. 
It is clear that the model would significantly benefit from further studies on 
spaceflight. Though the model has to overcome the many unknown variables of bone 
remodeling, bisphosphonates, and microgravity, it has shown the ability to provide 
potential trends for future studies. As new data and information becomes available, the 
model's accuracy can only be improved and could eventually be a tool used for 
predicting effects ofother treatments as well. 
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SUMMARY OF CONCLUSIONS
• The model predicted bisphosphonates reduced fracture risk by increasing bone 
quantity and either increasing or only slightly reducing bone quality for 
treatments: 
• (l) with low to intermediate suppression of remodeling activation 
• (2) that create higher bone balance ratios 
• Most changes to BMD occurred early on when adjusting to new environments 
• Predicted BMD loss was fairly consistent with data from missions to the 
International Space Station 
• Preflight treatments were shown to reduce the risk of fracture for all durations of 
spaceflight 
• Longer preflight treatment periods may put the subject at risk due to increased 
microdarnage accumulation 
• Overal~ the model suggested that bisphosphonate treatment, combined with 
existing exercise programs, may be the solution to combat bone deterioration in 
space 
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APPENDIX A: MATLAB CODE
%Bone Mass Preservation and Fracture Risk Assessment 
%with Bisphosphonate Therapy During Spaceflight 
%Simulation of Bisphosphonates acting on Bone Remodeling in Space 
%Chris Gardina 6-10-08 
% 
clear 
clc 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% Remodeling parameters 
Rc 0.095; % Cement line radius 
Rh 0.020; % Haversian canal radius 
Tr 25; % Resorption period 
Tv 5; % Reversal period 
Tf 64; % Formation period 
trab1 = 0.2; % Porosity partition for cortical 
to trabecular bone: Change resorption area & Disuse 
trab2 = 0.097267787; % Porosity partition for cortical 
to trabecular bone: Change in stiffness constants 
phiO = 0.0000000001875; % Equilibrium stimulus 
%porO = 0.2; % Initial trabecular porosity 
porO = 0.04432132964; % Initial cortical porosity 
saO = ((((28.8*porO-101)*porO+134)*porO-93.9)*porO+32.1)*por0; % 
Initial surface area 
phc=0.04432132964; % Adjusts resorption rate to match 
apposition rate for cortical bone (i.e., 
% assumes resorption process 
includes void spaces) 
% Activation frequency conditions 
% Describes Ac.f versus disuse and Ac.f versus damage curves 
Acfmax1 = 0.5; % Maximum Ac.f due to damage 
Acfmax2 = 0.5; % Maximum Ac.f due to disuse 
samax = 4.1905; % Normalizes specific area 
AcfdisO = 0.0; % Equilibrium Ac.f for disuse 
AcfdamO = 0.0224693284; % Equilibrium Ac.f for damage 
AcfO = (AcfdamO + AcfdisO)*saO/samax; % Equilibrium Ac.f 
kb 65000000000; 
kc = phiO/2; 
% Damage conditions 
fs = 5; % Damage repair factor 
dO = 0.03662944; % Equilibrium damage 
if porO <= trab1 
kd dO*AcfO* (pi*Rc A 2) *fs/phiO; % Equilibrium damage constant 
else 
kd 0.5*dO*AcfO*(pi*RC A 2)*fs/phiO; 
end 
kr = -1.6; 
% Mechanical conditions 
Area = 100; % Cross-sectional area of bone 
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rl1 = 3000; % Frequency of loading in no. of 
cycles per day 
q = 4; % exponent of mechanical stimulus 
change = 0; % percent change in force 
chgper = 1; % time period of force change 
days = 7300; % Time length of initial value 
Setup 
flight = 180; % Time length of spaceflight 
postflight = 7300; % Time length of return to earth 
dt = 1; % Time step; One day 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%% 
%Loop through values of tau, Pmax, and bone balance 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%% 
for x=1:3 
if (x == 1) 
Pmax=O;
end
if (x == 2)
Pmax=O.7;
end
if (x == 3)
Pmax 1;
end
for y=1:2
if (y == 1) 
tau=S;
end
if (y == 2)
tau=20;
end
for z=1:2
if (z == 1) 
area r ratio=S./6; %bone balance 1.2 
end 
if (z == 2) 
area_r_ratio=10./13; %bone balance 1.3 
end 
if Pmax == 0 
area r ratio=l; %no drug therapy, 
bone balance 1 
end 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% Prior conditions before start of simulation 
for t=l: (Tr+Tv+Tf) 
por(t) = porO; % porosity 
if por(t) <= trab2 
modulus(t) = 23440*(1-por(t))AS . 74 ; %Stiffness 
of bone if cortical 
else 
modulus(t) 14927* (l-por (t)) A 1 . 33; %Stiffness 
of bone if trabecular 
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end 
Phi(t) = phiO, 
mechanical stimulus 
strain(t) (phiO/rll)A O. 25 , 
strain 
stress (t) modulus(t)*strain(t) , 
stress 
Force(t) = stress(t)*Area, 
bone 
SA(t) = saO/samax, 
normalizes Ac.f by available surface area 
Df (t) kd*phiO, 
formation rate 
Dr (t) dO*ACfO*(pi*Rc A 2)*fs, 
removal rate 
if por (t) > trabl 
Dr(t) O.5*Dr(t) , 
end 
D (t) = dO, 
NfBMU(t) AcfO*Tf; 
refillng BMUs 
NrBMU (t) AcfO*Tr; 
resorbing BMUs 
if por(t) <= trabl 
Qf(t) 
apposition rate 
Qr(t) 
resorption rate 
QrNr(t) 
bone removed 
QfNf(t) 
bone added 
else 
Qf (t) 
Qr(t) 
QrNr (t) 
QfNf(t) 
end 
A Api*(Rc 2-Rh 2)/Tf, 
(l-phc)*Qr(t)*NrBMU(t) , 
Qf (t) *NfBMU (t) , 
AO.5*pi*Rc 2/Tf,
AO.5*pi*Rc 2/Tr, 
Qr (t) *NrBMU (t) , 
= Qf(t)*NfBMU(t), 
% 
% principal 
% principal 
% force on 
% 
% damage 
% damage 
% damage 
% No. of 
% No. of 
% mineral 
% 
% amount 
% amount of 
Qnet(t) = QfNf(t)-QrNr(t), % 
difference between mineral added and mineral removed 
Acfdam(t) AcfdamO; % Ac.f due 
to damage 
Acfdis(t) AcfdisO, % Ac. f due 
to disuse 
Acf(t) = (Acfdam(t) + Acfdis(t))*SA(t), % Total 
Ac.f 
TIME(t) = t, 
end 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%Adding 
Treatment%%%%%%%%%%%%%%%% 
% Pmax=O.7, 
% Pmax=l, 
% tau=5, 
in Constants for Bisphonate 
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% tau=20; 
%area_r_ratio=l; %bone balance 1 
% area_r_ratio=S./6; %bone balance 1.2 
% area_r_ratio=10./13; %bone balance 1.3 
preflight_treat = 0; %Days of Bisphosphonate 
therapy before spaceflight 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% Simulation 
for t=(Tr+Tv+Tf+l): (days+flight+postflight) 
TIME(t) = t; 
% Mechanical conditions upduate 
if por(t-l) <= trab2 
modulus(t) = 23440*(1-por(t-l))AS . 74 ; %Stiffness 
of bone if cortical 
else 
modulus(t) 14927*(1-por(t-l))A1 . 33 ; %Stiffness 
of bone if trabecular 
end 
if (t > (days)) && (t < (days + flight + 1)) 
Force(t) = 89.09; %Force in 
spaceflight to match 0.7%BMD loss per month 
%Force(t) = 85.47; %Force 
in spaceflight to match 1.0%BMD loss per month 
else 
Force(t) = 100; %Force 
needed to determine initial values 
end 
stress(t) Force(t)/Area; %Stress on 
bone 
strain(t) stress(t)/modulus(t) ; %Strain on 
bone 
% Porosity update 
Phi(t) = (abs(strain(t))Aq )*rll; %Calculate 
current stimulus 
if por(t-l) <= 0.2 
area f = pi*(RcA2-RhA2); 
%Formation area of cortical bone (Cement line to Haversian canal) 
if (t > (days - preflight_treat)) && (t < (days 
+ flight + 1)) %Bisphosphate treatment period 
area_r=area_r_ratio*pi*RcA2; 
%Resorption area if cortical & on Bisphosphonates 
else 
area r = pi*RcA2; 
%Resorption area if cortical 
end
else A
area f = 0.5*pi*Rc 2; 
% Formation area of trabecular bone (half of osteon area w/o pore) 
if (t > (days - preflight_treat)) && (t < (days 
+ flight + 1)) %Bisphosphate treatment period 
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area r = area_r_ratio*0.S*pi*Rc A 2; 
%Resorption area if trabecular & on Bisphosphonates 
else 
area r = 0.S*pi*Rc A 2; 
%Resorption area if trabecular 
end 
end 
% Calculate change in damage level and update 
Of (t) kd*Phi (t) ; %Damage 
formation rate 
Dr(t) D(t-I)*Acf(t-I)*area r*fs; %Damage 
removal rate 
D(t) = D(t-I) + (Df(t) - Dr(t)) *dt; %Damage 
update 
% Calculate demand for new BMUs (Ac.f) 
Acfdam(t) = (AcfdamO*AcfmaxI)/(AcfdamO+(AcfmaxI­
AcfdamO)*exp(kr*AcfmaxI*(D(t-I)-dO)/dO)); %Damage stimulus 
if D(t) <= dO 
Acfdam(t) = AcfdamO*D(t-I)/dO; 
end 
sa = ((((28.8*por(t-I)-101)*por(t-I)+134)*por(t-I)­
93.9)*por(t-l)+32.1)*por(t-I); %Surface area 
Acfdis(t) 0; % No demand for additional 
remodeling if not in disuse 
if Phi(t) < phiO 
Acfdis(t) = Acfmax2/(I+exp(kb*(Phi(t)-kc))); 
% Demand for remodeling when bone is in disuse 
end 
SA(t)=sa/samax; 
Acf(t) = (Acfdam(t) + Acfdis(t) )*SA(t); 
%Update Ac.f 
% Calculate daily amount of bone removed per 
resorbing BMU 
% Include less refilling on trabecular surfaces in 
disuse 
ac area r; % Resorption 
area 
ab area f; % Formation area 
Qf(t) ab/Tf; 
Qr(t) aC/Tr; 
if por(t-I) > trabl 
if Phi(t) < phiO 
Qf(t) (O.S + O.S*Phi(t)/phiO)*Qf(t); % 
For trabecular bone, formation rate decreases in disuse 
end 
end 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%% bisphosphonate potency effect 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
if (t > (days - preflight treat)) && (t < 
(days+flight+l) ) %Bisphosphate treatment period 
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P=Pmax*(l-exp(-l*tau*NrBMU(t-l))) ; 
% P=l; %completely suppressed 
Acf(t) = (l-P)*(Acfdam(t) + Acfdis(t))*SA(t); 
%Bisphosphonate suppressed activation frequency 
end 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% Calculate number of refilling BMUs for current 
day 
% Calculate number of resorbing BMUs for current 
day 
NfBMU (t) NfBMU (t-l) + (Acf(t-Tr-Tv) - Acf(t-Tr-
Tv-TO) *dt; 
NrBMU (t) NrBMU (t-l) + (Acf(t) - Acf(t-Tr))*dt; 
% Calculate net amount of bone added per day 
QfNf(t) = NfBMU(t-l)*Qf(t-l) + (Acf(t-Tr-Tv)*Qf(t­
Tr-Tv) - Acf(t-Tr-Tv-Tf)*Qf(t-Tr-Tv-Tf))*dt; 
QrNr(t) NrBMU(t-l) *Qr(t-l) + (Acf(t) *Qr(t) ­
Acf(t-Tr)*Qr(t-Tr) )*dt; 
Qnet(t) QfNf(t)-QrNr(t); 
if por(t-l) <= 0.20 
Qnet(t) = QfNf(t) - (l-phc)*QrNr(t); 
end 
% Calculate change in porosity 
por(t) (por(t-l) - Qnet(t))*dt; 
BMD(t) = 2*(1-por(t)); 
uplim = 0.99;
if por(t) >= uplim;
por (t) = uplim;
end
end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%Format data in charts 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
if (Pmax == O)&&(tau == 5)&&(area_r_ratio==1) 
for t=l: (days+flight+postflight) 
DataPOal (t, : ) 
[TIME(t) ,Of(t) ,Or(t) ,O(t) ,BMD(t)]; 
end 
save DataPOal.txt DataPOal -ascii -double 
end 
if (Pmax == 0.7)&&(tau == 5)&&(area r ratio==l) 
for t=l: (days+flight+postflight) 
DataP07t5al(t, :) 
(TIME(t) ,Df(t) ,Dr(t) ,D(t) ,BMD(t)]; 
end 
save DataP07t5al.txt DataP07t5al -ascii -double 
end 
if (Pmax == 0.7)&&(tau == 5)&&(area_r ratio==5./6) 
for t=l: (days+flight+postflight) 
DataP07t5a12(t, :) 
(TIME(t) ,Df(t) ,Dr(t) ,D(t) ,BMD(t)]; 
end 
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save OataP07t5a12.txt DataP07t5a12 -ascii ­
double 
end 
if (Pmax == O.7)&&(tau == 5)&&(area r ratio==lO./13) 
for t=l: (days+flight+postflight) 
DataP07t5a13(t, :) 
[TIME(t) ,Df(t) ,Or(t) ,D(t) ,BMD(t)];
end
save OataP07t5a13.txt DataP07t5a13 -ascii ­
double 
end 
if (Pmax == O.7)&&(tau == 20)&&(area r_ratio==l) 
for t=l: (days+flight+postflight) 
DataP07t20al(t, :) 
[TIME (t) ,Df (t) ,Dr (t) ,0 (t) , BMD (t) ] ;
end
save DataP07t20al.txt DataP07t20al -asci'
double 
end 
if (Pmax == O.7)&&(tau == 20)&&(area r ratio==5./6) 
for t=l: (days+flight+postflight) 
OataP07t20a12(t, :) 
[TIME (t) ,Of (t) ,Dr (t) ,0 (t) ,BMD (t) ] ;
end
save OataP07t20a12.txt OataP07t20a12 -ascii ­
double 
end 
if (Pmax == O.7)&&(tau == 
20)&&(area_r_ratio==lO./13) 
for t=l: (days+flight+postflight) 
DataP07t20a13(t, :) 
[TIME(t) ,Df(t) ,Dr(t) ,D(t) ,BMD(t)];
end
save DataP07t20a13.txt DataP07t20a13 -ascii ­
double 
end 
if (Pmax == l)&&(tau == 5)&&(area_r_ratio==1) 
for t=l: (days+flight+postflight) 
DataPlt5al(t, :) 
[TIME(t) ,Of (t) ,Or(t) ,D(t) ,BMD(t)] ; 
end 
save DataPlt5al.txt DataPlt5al -ascii -double 
end 
if (Pmax == l)&&(tau == 5)&&(area_r_ratio==5./6) 
for t=l: (days+flight+postflight) 
DataPlt5a12(t, :) 
[TIME (t) , Df (t) ,Dr (t) ,0 (t) , BMD (t) ] ; 
end 
save DataPltSa12.txt DataPltSa12 -ascii -double 
end 
if (Pmax == l)&&(tau == 5)&&(area_r_ratio==lO./13) 
for t=l: (days+flight+postflight) 
DataPlt5a13(t, :) 
[TIME(t) ,Of(t) ,Dr(t) ,D(t) ,BMD(t)];
end
save DataPltSa13.txt OataPlt5a13 -ascii -double
end 
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if (Pmax == l}&&(tau == 20)&&(area_r_ratio==1) 
for t=l: (days+flight+postflight) 
DataPlt20al(t, :) 
[TIME(t} ,Df (t) ,Dr(t) ,D(t) ,BMD(t)]; 
end 
save DataPlt20al.txt DataPlt20al -ascii -double 
end 
if (Pmax == l)&&(tau == 20)&&(area_r_ratio==5./6) 
for t=l: (days+flight+postflight) 
DataPlt20a12(t, :) 
[TIME(t) ,Df(t) ,Dr(t) ,D(t) ,BMD(t)];
end
save DataPlt20a12.txt DataPlt20a12 -ascii ­
double 
end 
if (Pmax == l)&&(tau == 20)&&(area_r_ratio==lO./13) 
for t=l: (days+flight+postflight) 
DataPlt20a13(t, :) 
[TIME(t) ,Df(t) ,Dr(t) ,D(t) ,BMD(t)];
end
save DataPlt20a13.txt DataPlt20a13 -ascii ­
double 
end 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%End of formating data in charts 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
end 
end 
end 
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APPENDIX B: FIGURES (to-DAY SPACEFLIGHT) 
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Figure 81. Predicted bisphosphonate effects on 8MD and posttreatment return to Earth from to-day 
spaceflight. 
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Figure 82. Predicted bisphosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from to-day spaceflight 
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Figure B3. Predicted bisphosphonate effects on BMD and posttreatment return to Earth from to-day 
spaceflight. 
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Figure B4. Predicted bisphosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from to-day spaceflight 
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Figure 85. Predicted bisphosphonate effects beginning 7 days preflight on HMD and posttreatment 
return to Earth from lO-day spaceflight. 
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Figure 86. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (D) 
and posttreatment return to Earth from to-day spaceflight. 
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Figure 87. Predicted bisphosphonate effects beginning 7 days preflight on 8MD and posttreatment 
return to Earth from to-day spaceflight. 
1.5 --- --------Relurn 10 Earth 
0.5 
0 
23 53 83 113 143 
-0.5 
• 
l
.. 
• 
• No Bisphosphonales 
P115a13 
r -1 
.. 
• 
.. P1I20a13 
P0715a13 
~
-1.5 • 
x P07120a13 
-2 
-2.5 
-3 
-3.5 _.... _J _~~~
Time (day) 
Figure 88. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (D) 
and posttreatment return to Earth from to-day spacenight. 
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Figure 89. Predicted bisphosphonate effects beginning 14 days preflight on 8MD and posttreatment 
return to Earth from 10-day spaceflight. 
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Figure 810. Predicted bisphosphonate effects beginning 14 days preflight on damage accumulation 
(D) and posttreatment return to Earth from to-day spaceflight 
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Figure 811. Predicted bisphosphonate effects beginning 14 days preflight on 8MD and posttreatment 
return to Earth from 10-day spaceflight. 
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Figure 812. Predicted bisphosphooate effects beginning 14 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 10-day spaceflight. 
63 
-2.5 
2.5 
Return to Earth 
1.5 
0.5 
• No Bisphosphonales 
" P1t5a12 
o 150 180 210 240 
• P1t20a12::E
!1! -0.5 - P0715a12 
.. P07120a12 
-1 
-1.5 
-2 
-2.5 
-3 
Time (day) 
Figure B13. Predicted bisphosphonate effects beginning 30 days preflight on BMD and posttreatment 
return to Earth from to-day spaceflight. 
2.5 .,----T--:::----:::---: 
2 
1.5 
0.5 . 
- 0 r-~11..... • No Bisphosphonales iiii;;:.::::;:::;;;;~==:':==~:;;:::::;=:~====_:'::-_==_____=_:_::_~~-~~:_i~ - 0 0 30 60 90 120 150 18(J'-71 330 360 
II • " Pl15a12
lil' -05 
.. P1t20a12
II 
­ P07t5a12~ -1 .. P07120a12
E
• 
• 
•
•
-1.5 
-2 
-2.5 
-3 
-3.5 
Time (day) 
Figure Bt4. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(D) and posttreatment return to Earth from to-day spaceflight. 
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Figure B15. Predicted bisphosphonate effects beginning 30 days preflight on BMD and posttreatment 
return to Earth from to-day spaceflight. 
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Figure Bt6. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 10-day spaceflight 
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Figure BJ 7. Predicted bisphosphonate effects beginning 90 days preflight on BMO and posttreatment 
return to Earth from to-day spaceflight. 
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Figure BJ8. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(0) and posttreatment return to Earth from to-day spaceflight. 
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Figure 819. Predicted bisphosphonate effects beginning 90 days preflight on 8MD and posttreatment 
return to Earth from to-day spaceflight. 
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Figure 820. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(D) and posttreatment return to Earth from to-day spaceflight. 
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Figure 821. Predicted bisphosphonate effects beginning 180 days preflight on 8MD and 
posttreatment return to Earth from 10-day spaceflight. 
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Figure Bn. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 10-day spaceflight 
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Figure 823. Predicted bisphosphonate effects beginning 180 days preflight on 8MD and 
posttreatment return to Earth from 10-day spaceflight. 
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Figure 824. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 10-day spaceflight 
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APPENDIX C: FIGURES (90-DAY SPACEFLIGHT) 
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Figure Cl. Predicted bisphosphonate effects on HMD and posttreatment return to Earth from 90-day 
spaceflight. 
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Figure C2. Predicted bisphosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from 90-day spaceflight. 
70 
2.5 Return to Earth 
1.5 
0.5 
0 
180 210 240 270 300 330 360 390 420 
·1 
450 
-0.5 
~ -1 
c 
-1.5
::IE 
~
-2 
-2.5 
-3 
-3.5 
-4 
\
••
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
• 
• No Bisphosphonales 
P1t5a13 
-+ P1I20a13 
P07t5a13 
X P07120a13 
~
-4.5 
-5 
-5.5 
Time (day) 
Figure C3. Predicted bisphosphonate effects on BMD and posttreatment return to Earth from 90-day 
spaceflight. 
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Figure C4. Predicted bisphosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from 90-day spaceflight. 
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Figure C5. Predicted bisphosphonate effects beginning 7 days preflight on BMD and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure C6. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (D) 
and posttreatment return to Earth from 90-day spaceflight. 
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Figure C7. Predicted bisphosphonate effects beginning 7 days preflight on HMD and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure C8. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (D) 
and posttreatment return to Earth from 90-day spaceflight. 
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Figure C9. Predicted bisphosphonate effects beginning 14 days preflight on BMD and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure CI0. Predicted bisphosphonate effects beginning 14 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 90-day spaceflight. 
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Figure Cll. Predicted bisphosphonate effects beginning 14 days preflight on BMD and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure Cl2. Predicted bisphosphonate effects beginning 14 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 90-day spaceflight. 
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Figure cn. Predicted bisphosphonate effects beginning 30 days preflight on BMO and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure C14. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 90-day spaceflight 
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Figure CIS. Predicted bisphosphonate effects beginning 30 days preflight on BMO and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure C16. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 90-day spaceflight 
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Figure C17. Predicted bisphosphonate effects beginning 90 days preflight on BMD and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure CIS. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 90-day spaceflight. 
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Figure C19. Predicted bisphosphonate effects beginning 90 days preflight on HMO and posttreatment 
return to Earth from 90-day spaceflight. 
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Figure C20. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 90-day spaceflight 
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Figure C21. Predicted bispbospbonate effects beginning 180 days preflight on BMD and 
posttreatment return to Earth from 90-day spaceflight. 
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Figure C22. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 90-day spaceflight 
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Figure C23. Predicted bisphosphonate effects beginning 180 days preflight on BMO and 
posttreatment return to Earth from 90-day spaceflight. 
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Figure C24. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 90-day spaceflight 
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Figure DI. Predicted bisphosphonate effects on BMO and posttreatment return to Earth from 180­
day spaceflight. 
4.5 
"Om" ,.,"
0
1 0 210 240 270 300 330 360 390 420 450 480 510 540
-1.5
-3 
1.5 
~~~,~I 
• No Bisphosphonales~
. .. P115a12 
Dl 
-4.5 
• P1120a12~
.. 
- P0715a12 
c
..., 
.. P07120a12
-6 
-7.5 
-9 
-10.5 
-12 
-13.5 
Time (day) 
Figure 02. Predicted bisphosphonate effects on damage accumulation (0) and posttreatment return 
to Earth from 180-day spaceflight. 
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Figure 03. Predicted bisphosphonate effects on HMO and posttreatment return to Earth from 180­
day spaceflight. 
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Figure 04. Predicted bisphosphonate effects on damage accumulation (0) and posttreatment return 
to Earth from 180-day spaceflight. 
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Figure D5. Predicted bisphosphonate effects beginning 7 days prenight on BMO and posttreatment 
return to Earth from ISO-day spaceflight. 
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Figure D6. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (0) 
and posttreatment return to Earth from ISO-day spaceflight. 
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Figure D7. Predicted bisphosphonate effects beginning 7 days preflight on HMD and posttreatment 
return to Earth from 180-day spaceflight. 
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Figure D8. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (D) 
and posttreatment return to Earth from l80-day spaceflight. 
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Figure D9. Predicted bisphosphonate effects beginning 14 days preflight on BMD and posttreatment 
return to Earth from I80-day spaceflight. 
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Figure DIO. Predicted bisphosphonate effects beginning 14 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 180-day spaceflight. 
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Figure DI1. Predicted bisphosphonate effects beginning 14 days preflight on HMO and posttreatment 
return to Earth from 180-day spaceflight. 
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Figure 012. Predicted bisphosphonate effects beginning 14 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 180-day spaceflight. 
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Figure 013. Predicted bisphosphonate effects beginning 30 days preflight on HMO and posttreatment 
return to Earth from 180-day spaceflight. 
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Figure 014. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 180-day spaceflight. 
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Figure D15. Predicted bisphosphonate effects beginning 30 days preflight on BMD and posttreatment 
return to Earth from 180-day spaceflight. 
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Figure D16. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 180-day spaceflight. 
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Figure D17. Predicted bisphosphonate effects beginning 90 days preflight on HMD and posttreatment 
return to Earth from 180-day spaceflight. 
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Figure D18. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(D) and posttreatment return to Earth from ISO-day spaceflight. 
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Figure DI9. Predicted bisphosphonate effects beginning 90 days preflight on BMD and posttreatment 
return to Earth from 180-day spaceflight. 
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Figure D20. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 180-day spaceflight. 
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Figure 021. Predicted bisphosphonate effects beginning 180 days preflight on HMO and 
posttreatment return to Earth from I80-day spaceflight. 
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Figure 022. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(D) and posttreatment return to Earth rrom I80-day spaceflight. 
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Figure D23. Predicted bisphosphonate effects beginning 180 days preflight on BMD and 
posttreatment return to Earth from 180-day spaceflight. 
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Figure D24. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 180-day spaceflight. 
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Figure El. Predicted bisphosphonate effects on HMO and posttreatment return to Earth from 365­
day spaceflight. 
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Figure E2. Predicted bisphosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from 365-day spaceflight. 
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Figure E3. Predicted bisphosphonate effects on HMD and posttreatment return to Earth from 365­
day spaceflight. 
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Figure E4. Predicted bispbosphonate effects on damage accumulation (D) and posttreatment return 
to Earth from 365-day spaceflight. 
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Figure E5. Predicted bisphosphonate effects beginning 7 days preflight on BMD and posttreatment 
return to Earth from 365-day spaceflight. 
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Figure E6. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (D) 
and posttreatment return to Earth from 365-day spaceflight. 
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Figure E7. Predicted bisphosphonate effects beginning 7 days preflight on BMO and posttreatment 
return to Earth from 365-day spaceflight. 
9 
7.5 
6 
4.5 
1.5 
0 
-1.5 
• No Bisphosphonates! -3 Plt5a13 
r" -4.5 + Plt20a13 
II P0715a13 
-6~ II P07t20a13 
-7.5 
-9 
-10.5 
-12 
-13.5 
-15 
-16.5 
.,__. J
-18 ­
Time (day) 
Figure E8. Predicted bisphosphonate effects beginning 7 days preflight on damage accumulation (0) 
and posttreatment return to Earth from 365-day spaceflight. 
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Figure E9. Predicted bisphosphonate effects beginning 14 days preflight on HMD and posttreatment 
return to Earth from 365-day spaceflight. 
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Figure EI0. Predicted bisphosphonate effects beginning 14 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 365-day spaceflight. 
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Figure Ell. Predicted bisphospbonate effects beginning 14 days preflight on HMO and posttreatment 
return to Earth from 365-day spaceflight. 
~
.. 
-3 • No Bispllospllonates 
P1t5a13 
r -4.5 
.. 
~ -6 
+P1120a13 
P0715a13 
)( P07120a13 
-7.5 
-9 
-10.5 
-12 
-13.5 
-15 
-16.5 
-18 
Time (day) 
Figure E12. Predicted bisphosphonate effects beginning 14 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 365-day spaceflight. 
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Figure E13. Predicted bisphosphonate effects beginning 30 days preflight on HMO and posttreatment 
return to Earth from 365-day spaceflight. 
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Figure E14. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 365-day spaceflight. 
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Figure E15. Predicted bisphosphonate effects beginning 30 days preflight on BMD and posttreatment 
return to Earth from 365-day spaceflight 
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Figure E16. Predicted bisphosphonate effects beginning 30 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 365-day spaceflight. 
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Figure E17. Predicted bisphosphonate effects beginning 90 days preflight on HMD and posttreatment 
return to Earth from 365-day spaceflight. 
11 
9.5 
65 
3.5
2
0.5 
• No Bisphosphonates ~
.. I. Pll5a12 
r -2.5 • Plt20a12
.. 
-4 - P07t5a12~
.. P07t20a12 
-5.5
-7
-a.5
-10
-11.5
-13
-14.5
-16
-17.5
Time (day) 
Figure E18. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 365-day spaceflight. 
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Figure E19. Predicted bisphosphonate effects beginning 90 days preflight on 8M D and posttreatment 
return to Earth from 365-day spaceflight. 
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Figure E20. Predicted bisphosphonate effects beginning 90 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 365-day spaceflight. 
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Figure E21. Predicted bisphosphonate effects beginning 180 days preflight on BMO and 
posttreatment return to Earth from 365-day spaceflight. 
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Figure E22. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(0) and posttreatment return to Earth from 365-day spaceflight. 
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Figure E23. Predicted bisphosphonate effects beginning 180 days preflight on BMD and 
posttreatment return to Earth from 365-day spaceflight. 
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Figure E24. Predicted bisphosphonate effects beginning 180 days preflight on damage accumulation 
(D) and posttreatment return to Earth from 365-day spaceflight. 
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